Abcellera Biologics Valuation
| ABCL Stock | USD 2.95 0.19 6.88% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Abcellera Biologics shows a prevailing Real Value of $7.93 per share. The current price of the firm is $2.95. Our model approximates the value of Abcellera Biologics from analyzing the firm fundamentals such as return on equity of -0.16, and Operating Margin of (14.39) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Abcellera Biologics' valuation include:
Price Book 0.7562 | Enterprise Value 243.5 M | Enterprise Value Ebitda 5.3008 | Price Sales 24.7318 | Forward PE 27.4725 |
Undervalued
Today
Please note that Abcellera Biologics' price fluctuation is slightly risky at this time. Calculation of the real value of Abcellera Biologics is based on 3 months time horizon. Increasing Abcellera Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Abcellera stock is determined by what a typical buyer is willing to pay for full or partial control of Abcellera Biologics. Since Abcellera Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Abcellera Stock. However, Abcellera Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.95 | Real 7.93 | Target 23.88 | Hype 2.78 | Naive 2.7 |
The intrinsic value of Abcellera Biologics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Abcellera Biologics' stock price.
Estimating the potential upside or downside of Abcellera Biologics helps investors to forecast how Abcellera stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Abcellera Biologics more accurately as focusing exclusively on Abcellera Biologics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Abcellera Biologics' intrinsic value based on its ongoing forecasts of Abcellera Biologics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Abcellera Biologics' closest peers.
Abcellera Biologics Cash |
|
Abcellera Valuation Trend
Knowing Abcellera Biologics' actual value is paramount for traders when making sound investment determinations. Using both Abcellera Biologics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Abcellera Revenue by Product
Abcellera Biologics Total Value Analysis
Abcellera Biologics is presently forecasted to have valuation of 243.47 M with market capitalization of 815.21 M, debt of 77.38 M, and cash on hands of 868.21 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Abcellera Biologics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
243.47 M | 815.21 M | 77.38 M | 868.21 M |
Abcellera Biologics Investor Information
About 28.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.76. Some equities with similar Price to Book (P/B) outperform the market in the long run. Abcellera Biologics has Price/Earnings To Growth (PEG) ratio of 2.22. The entity recorded a loss per share of 0.61. The firm had not issued any dividends in recent years. Based on the key indicators related to Abcellera Biologics' liquidity, profitability, solvency, and operating efficiency, Abcellera Biologics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Abcellera Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Abcellera Biologics has an asset utilization ratio of 2.56 percent. This suggests that the Company is making $0.0256 for each dollar of assets. An increasing asset utilization means that Abcellera Biologics is more efficient with each dollar of assets it utilizes for everyday operations.Abcellera Biologics Ownership Allocation
Abcellera Biologics holds a total of 295.37 Million outstanding shares. Abcellera Biologics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Abcellera Biologics Profitability Analysis
The company reported the previous year's revenue of 38.02 M. Net Loss for the year was (146.4 M) with profit before overhead, payroll, taxes, and interest of 311.11 M.About Abcellera Biologics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Abcellera Biologics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Abcellera Biologics based exclusively on its fundamental and basic technical indicators. By analyzing Abcellera Biologics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Abcellera Biologics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Abcellera Biologics. We calculate exposure to Abcellera Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Abcellera Biologics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 38 M | 36.1 M | |
| Pretax Profit Margin | (4.58) | (4.35) | |
| Operating Profit Margin | (6.24) | (5.93) | |
| Net Loss | (3.85) | (3.66) | |
| Gross Profit Margin | 0.78 | 0.50 |
Abcellera Biologics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Abcellera Biologics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 289.2 M | |
| Quarterly Earnings Growth Y O Y | 0.459 | |
| Forward Price Earnings | 27.4725 |
Abcellera Biologics Current Valuation Indicators
Abcellera Biologics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Abcellera Biologics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Abcellera Biologics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Abcellera Biologics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Abcellera Biologics' worth.When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.459 | Earnings Share (0.61) | Revenue Per Share 0.112 | Quarterly Revenue Growth (0.01) | Return On Assets (0.13) |
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.